DIN 02552477 — TYENNE 400 MG
TYENNE is a solution of Tocilizumab marketed by FRESENIUS KABI CANADA LTD. The full Tocilizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02552477
- Brand name
- TYENNE
- Active ingredient
- Tocilizumab
- Strength
- 400 MG
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS
- Manufacturer
- FRESENIUS KABI CANADA LTD
- Health Canada status
- MARKETED
- Drug class
- Interleukin-6 (IL-6) receptor antagonist (monoclonal antibody biologic)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Tocilizumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02424770 | ACTEMRA | 162 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED |
| 02483327 | ACTEMRA | 162 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED |
| 02350106 | ACTEMRA | 200 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED |
| 02350114 | ACTEMRA | 400 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED |
| 02350092 | ACTEMRA | 80 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED |
| 02562057 | AVTOZMA | 162 MG | SOLUTION | CELLTRION INC. | MARKETED |
| 02562065 | AVTOZMA | 162 MG | SOLUTION | CELLTRION INC. | MARKETED |
| 02562030 | AVTOZMA | 200 MG | SOLUTION | CELLTRION INC. | MARKETED |
| 02562049 | AVTOZMA | 400 MG | SOLUTION | CELLTRION INC. | MARKETED |
| 02562022 | AVTOZMA | 80 MG | SOLUTION | CELLTRION INC. | MARKETED |
| 02552485 | TYENNE | 162 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED |
| 02552493 | TYENNE | 162 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED |
| 02552469 | TYENNE | 200 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED |
| 02552450 | TYENNE | 80 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED |